172 related articles for article (PubMed ID: 26398947)
1. Glycolytic inhibitor 2-deoxyglucose simultaneously targets cancer and endothelial cells to suppress neuroblastoma growth in mice.
Huang CC; Wang SY; Lin LL; Wang PW; Chen TY; Hsu WM; Lin TK; Liou CW; Chuang JH
Dis Model Mech; 2015 Oct; 8(10):1247-54. PubMed ID: 26398947
[TBL] [Abstract][Full Text] [Related]
2. 2-Deoxyglucose treatment complements the cisplatin- or BH3-only mimetic-induced suppression of neuroblastoma cell growth.
Chuang JH; Chou MH; Tai MH; Lin TK; Liou CW; Chen T; Hsu WM; Wang PW
Int J Biochem Cell Biol; 2013 May; 45(5):944-51. PubMed ID: 23395630
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of c-Myc is involved in TLR3-mediated tumor death of neuroblastoma xenografts.
Lin LL; Huang CC; Wu CL; Wu MT; Hsu WM; Chuang JH
Lab Invest; 2016 Jul; 96(7):719-30. PubMed ID: 27183205
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha.
Qing G; Skuli N; Mayes PA; Pawel B; Martinez D; Maris JM; Simon MC
Cancer Res; 2010 Dec; 70(24):10351-61. PubMed ID: 20961996
[TBL] [Abstract][Full Text] [Related]
5. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.
Johnsen JI; Segerström L; Orrego A; Elfman L; Henriksson M; Kågedal B; Eksborg S; Sveinbjörnsson B; Kogner P
Oncogene; 2008 May; 27(20):2910-22. PubMed ID: 18026138
[TBL] [Abstract][Full Text] [Related]
7. Glycolytic inhibitor 2-deoxy-d-glucose suppresses cell proliferation and enhances methylprednisolone sensitivity in non-Hodgkin lymphoma cells through down-regulation of HIF-1α and c-MYC.
Pang YY; Wang T; Chen FY; Wu YL; Shao X; Xiao F; Huang HH; Zhong H; Zhong JH
Leuk Lymphoma; 2015 Jun; 56(6):1821-30. PubMed ID: 25219592
[TBL] [Abstract][Full Text] [Related]
8. Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens.
Rodríguez-Hernández CJ; Mateo-Lozano S; García M; Casalà C; Briansó F; Castrejón N; Rodríguez E; Suñol M; Carcaboso AM; Lavarino C; Mora J; de Torres C
Oncotarget; 2016 Mar; 7(13):16112-29. PubMed ID: 26893368
[TBL] [Abstract][Full Text] [Related]
9. FX11 inhibits aerobic glycolysis and growth of neuroblastoma cells.
Rellinger EJ; Craig BT; Alvarez AL; Dusek HL; Kim KW; Qiao J; Chung DH
Surgery; 2017 Mar; 161(3):747-752. PubMed ID: 27919448
[TBL] [Abstract][Full Text] [Related]
10. FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma.
Jiang P; Huang M; Qi W; Wang F; Yang T; Gao T; Luo C; Deng J; Yang Z; Zhou T; Zou Y; Gao G; Yang X
J Exp Clin Cancer Res; 2019 Sep; 38(1):400. PubMed ID: 31511046
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression.
Taylor JS; Zeki J; Ornell K; Coburn J; Shimada H; Ikegaki N; Chiu B
J Pediatr Surg; 2019 Jun; 54(6):1192-1197. PubMed ID: 30879743
[TBL] [Abstract][Full Text] [Related]
12. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2.
Xiao D; Ren P; Su H; Yue M; Xiu R; Hu Y; Liu H; Qing G
Oncotarget; 2015 Dec; 6(38):40655-66. PubMed ID: 26528759
[TBL] [Abstract][Full Text] [Related]
13. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.
Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G
Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519
[TBL] [Abstract][Full Text] [Related]
14. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.
Tateishi K; Iafrate AJ; Ho Q; Curry WT; Batchelor TT; Flaherty KT; Onozato ML; Lelic N; Sundaram S; Cahill DP; Chi AS; Wakimoto H
Clin Cancer Res; 2016 Sep; 22(17):4452-65. PubMed ID: 27076630
[TBL] [Abstract][Full Text] [Related]
15. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
[TBL] [Abstract][Full Text] [Related]
16. Tumor origin of endothelial cells in human neuroblastoma.
Pezzolo A; Parodi F; Corrias MV; Cinti R; Gambini C; Pistoia V
J Clin Oncol; 2007 Feb; 25(4):376-83. PubMed ID: 17264333
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[
Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H
Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970
[TBL] [Abstract][Full Text] [Related]
18. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of thioredoxin-1 enhances the toxicity of glycolysis inhibitor 2-deoxyglucose by downregulating SLC1A5 expression in colorectal cancer cells.
Tang T; Fang D; Ji Z; Zhong Z; Zhou B; Ye L; Jiang L; Sun X
Cell Oncol (Dordr); 2024 Apr; 47(2):607-621. PubMed ID: 37867183
[TBL] [Abstract][Full Text] [Related]
20. Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.
Waldeck K; Cullinane C; Ardley K; Shortt J; Martin B; Tothill RW; Li J; Johnstone RW; McArthur GA; Hicks RJ; Wood PJ
Int J Cancer; 2016 Jul; 139(1):194-204. PubMed ID: 26914605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
